Amyloidosis

Postgraduate Medical Journal

Volumn 77, Issue 913, 2001, Pages 686-693

  Khan, M F ^a   Falk, R H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amyloidosis

Indexed keywords

4' IODOESORUBICIN; AMYLOID; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; ETANERCEPT; MELPHALAN; MIDODRINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VINCRISTINE;

AMYLOIDOSIS; BIOACCUMULATION; CLINICAL FEATURE; DISEASE COURSE; EARLY DIAGNOSIS; ELECTROPHORESIS; HEMODIALYSIS; HUMAN; IMMUNOMODULATION; PATHOPHYSIOLOGY; PROGNOSIS; QUALITY OF LIFE; REVIEW; SURVIVAL; SYNDROME DELINEATION;

AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DIURETICS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; ORGAN TRANSPLANTATION; PROGNOSIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0034752111     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.77.913.686     Document Type: Review

References (84)

1. Cases of lardaceous disease and some allied affections, with remarks
2. History of amyloidosis
3. Eine spezifische amyloidfarbung mit kongorot
4. Electron microscopic observations on a fibrous component in amyloid of diverse origins
5. High-resolution electron microscopic analysis of the amyloid fibril
6. Characterization of the amyloid fibril as a cross-beta protein
7. Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component
8. Further characterization of amyloid-enhancing factor
9. Proteoglycans, glycosaminoglycans, amyloid-enhancing factor, and amyloid deposition
10. A chemical classification of amyloid. Correlation with different clinical types of amyloidosis
11. The systemic amyloidoses
12. Amyloid fibril proteins: Proof of homology with immunoglobulin light chains by sequence analyses
13. The systemic amyloidoses: An overview
14. Primary systemic amyloidosis: Multivariate analysis for prognostic factors in 168 cases
15. The major proteins of human and monkey amyloid substance: Common properties including unusual N-terminal amino acid sequences
16. Protein AA/SAA
17. The N-terminal segment of protein AA determines its fibrillogenic property
18. Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis. A histochemical study
19. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis
20. Secondary systemic amyloidosis: Response and survival in 64 patients
21. Variant apolipo-protein AI as a major constituent of a human hereditary amyloid
22. Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain
23. Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene
24. Transthyretin amyloidosis
25. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy
26. Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis
27. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans
28. Revised transthyretin Ile 122 allele frequency in African-Americans
29. A new form of amyloid protein associated with chronic hemodialysis was identified as beta 2-microglobulin
30. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
31. Secreted amyloid beta-protein similar to that in the senile plaques of Alzeimer's disease is increased in vivio by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
32. Cardiac amyloidosis
33. Atrial amyloid deposits in the failing human heart display both atrial and brain natriuretic peptide-like immunoreactivity
34. Senile cardiac amyloidosis with myocardial dysfunction. Diagnosis by endomyocardial biopsy and immunohistochemistry
35. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis
36. Amyloidosis
37. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases
38. Pupil abnormality in amyloidosis with autonomic neuropathy
39. The liver in systemic amyloidosis: Insights from 123I serum amyloid P component scintigraphy in 484 patients
40. Alopecia universalis. A manifestation of occult amyloidosis and multiple myeloma
41. Reduced taste perception in AL amyloidosis. A frequently unnoticed sensory impairment
42. Skin manifestations of internal disease
43. Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X
44. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement
45. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis
46. Imaging amyloidosis with radiola-belled SAP
47. Clinical improvement and amyloid regression after amyloid transplantation in hereditary transthyretin amyloidosis
48. Amyloid P component and the diagnosis of amyloidosis
49. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression
50. Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis
51. Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years' experience
52. Light and electron microscopy immunohistochemical characterization of amyloid deposits
53. Seperation of hybrid isoelectric fousing of normal human plasma transthyretin (prealbumin) and a variant with a methionine for valine substitution associated with familial amyloidotic polyneuropathy
54. Immunohistochemistry of amyloid
55. Treatment of primary amyloidosis
56. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents
57. Digoxin sensitivity in amyloid cardiomyopathy
58. Amyloidosis
59. Efficacy of midodrine versus placebo in neurogenic orthostatic hypotension: A randomised, double-blind multicenter study
60. Treatment of orthostatic hypotension with erythropoietin
61. Survival of patients with primary (AL) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973)
62. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine
63. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only
64. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine
65. Intensive chemotherapy for AL amyloidosis
66. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients
67. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients
68. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis
69. Treatment of AL amyloidosis with 4′-iodo-4′-deoxydoxorubicin: An update
70. Cardiac transplantation for AL amyloidosis
71. Heart transplantation in AL amyloidosis
72. Antitumor activity of thalidomide in refractory multiple myeloma
73. Therapy with TNF-r Enbrel® results in remarkable symptom relief in patients (pts) with advanced primary amyloidosis (AL)
74. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30)
75. Liver transplantation as a treatment for familial amyloidotic polyneuropathy
76. Domino liver transplants for metabolic disorders: Experience with familial amyloidotic polyneuropathy
77. Familial amyloidotic polyneuropathy: Domino liver transplantation
78. Domino liver transplantation for familial amyloid polyneuropathy: Optimal use of a scarce resource
79. On the formation and disappearance of amyloid in man
80. Prolonged colchicine treatment in four patients with amyloidosis
81. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever
82. Amyloidosis in juvenile chronic arthritis
83. Dialysis-related amyloidosis
84. Does dialysis-associated amyloidosis resolve after transplantation?